FSD Pharma Inc C.HUGE

FSD Pharma Info part 2

[DavidRosenberg]

FSD Pharma Growth Strategy

• Pursue further acquisition targets or potential investments that are unique and align with our mission of Total Brain Health
• Begin the process of advancing clinical trials for its compound Lucid-21-302, for the novel treatment of progressive MS (Multiple Sclerosis)
• Begin the process of advancing clinical trials for the treatment of depression, anxiety and psychiatric disorders through its psychedelic molecule Lucid-201
• Assess the best path forward for the advancement of FSD-201
• Complete the sale of our Cobourg property to increase cash in a non-dilutive method

Lucid Acquisition

• FSD Pharma acquired Lucid in September 2021
• Two unique pre-clinical lead drug candidates aimed to treat neurodegenerative diseases and neuropsychiatric disorders
  • LUCID-21-302 – target treatment: Multiple Sclerosis
  • LUCID-201 – target treatment: depression & anxiety
• New Chemical Entities (NCEs) with patents licensed from UHN (largest healthcare research organization in NA) and uniquely paired with psychedelics formulations to improve patient outcomes
• Large addressable markets: $23B¹ multiple sclerosis market and growing multibillion-dollar mental health market

FSD-201: Ultra Micro-PEA Compound

• Proprietary ultra micro-PEA formulation enhances the anti-inflammatory properties of PEA, a fatty acid amide currently used as a dietary supplement, by increasing its bioavailability and efficacy- making it suitable to treat a range of inflammatory conditions
• Holds exclusive worldwide licensing rights (except Italy & Spain) to ultra micro-PEA for all conditions in all regulatory categories
• Strong IP portfolio covering ultra-micronized composition of matter and use (2029-34 U.S. expiration)
  • Lead candidate (FSD 201- 600mg ultra micro-PEA)
  • Successfully completed Phase 1 first-in-human safety and tolerability trial. No serious adverse effects discovered
  • Toxicology trials have been completed and the results are being compiled
• Potential Target indications for Phase 2 trials currently being analyzed

Growing Market Opportunity in Psychedelics

• Growing body of research that suggests Psychedelics have the potential to treat a variety of neuropsychiatric disorders such as PTSD, depression, specifically complex TRD and MDD, and anxiety

FDA approval of Johnson & Johnson’s SPRAVATO (esketamine) for treatment-resistant depression

Meaningful MAPS Ph2 clinical data on MDMA-assisted psychotherapy for PTSD treatment

Expanding pipeline of psychedelic-based therapies

• $225B annual spend for mental health in the U.S.

Comparable Companies

as of September 27, 2021

[Walter333]

Imo FSD is a company with a gambling banker and a washed up wanna be DJ pumping on multiple accounts and platforms.

[Mil_Man54]

If I could give this more than 1 thumbs up...I would...